Humanized antibodies for therapy
- 1 June 1991
- journal article
- research article
- Published by Springer Nature in Nature
- Vol. 351 (6326) , 501-502
- https://doi.org/10.1038/351501a0
Abstract
Protein engineering has made it possible to combine the binding sites of murine antibodies with human antibody regions. Antibodies constructed in this way have important advantages for therapy.This publication has 10 references indexed in Scilit:
- Humanized antibodies for antiviral therapy.Proceedings of the National Academy of Sciences, 1991
- Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival.Proceedings of the National Academy of Sciences, 1991
- Monoclonal-Antibody Therapy in Systemic VasculitisNew England Journal of Medicine, 1990
- ANTI-TAC-H, A HUMANIZED ANTIBODY TO THE INTERLEUKIN-2 RECEPTOR WITH NEW FEATURES FOR IMMUNOTHERAPY IN MALIGNANT AND IMMUNE DISORDERS1990
- A humanized antibody that binds to the interleukin 2 receptor.Proceedings of the National Academy of Sciences, 1989
- REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1HThe Lancet, 1988
- Reshaping human antibodies for therapyNature, 1988
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986
- ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSIONTransplantation, 1986
- Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.Proceedings of the National Academy of Sciences, 1984